iifl-logo

Laurus Labs Ltd Share Price

598.9
(-2.36%)
Apr 1, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open611
  • Day's High617.8
  • 52 Wk High646.2
  • Prev. Close613.4
  • Day's Low594.95
  • 52 Wk Low 385.45
  • Turnover (lac)8,079.11
  • P/E132.57
  • Face Value2
  • Book Value80.4
  • EPS4.63
  • Mkt. Cap (Cr.)32,295.83
  • Div. Yield0.13
View All Historical Data

Laurus Labs Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

611

Prev. Close

613.4

Turnover(Lac.)

8,079.11

Day's High

617.8

Day's Low

594.95

52 Week's High

646.2

52 Week's Low

385.45

Book Value

80.4

Face Value

2

Mkt Cap (₹ Cr.)

32,295.83

P/E

132.57

EPS

4.63

Divi. Yield

0.13

Laurus Labs Ltd Corporate Action

25 Apr 2024

12:00 AM

BookCloser

arrow

24 Oct 2024

12:00 AM

Dividend

Dividend Amount: 0.4

Record Date: 06 Nov, 2024

arrow

6 Jan 2025

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

25 Apr 2024

12:00 AM

AGM

Announcement Date: 25 Apr, 2024

arrow

Laurus Labs Ltd NEWS AND UPDATE

Laurus Labs plans to invest ₹833 Crore in JV with Slovenian
7 Mar 2025|08:53 AM

The said transaction falls under related party transactions. However, the same is being carried at arm’s length price.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Laurus Labs Ltd SHAREHOLDING SNAPSHOT

01 Apr, 2025|04:57 AM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 27.62%

Foreign: 0.00%

Indian: 27.62%

Non-Promoter- 38.29%

Institutions: 38.29%

Non-Institutions: 34.08%

Custodian: 0.00%

Share Price

Laurus Labs Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

107.79

107.73

107.47

107.32

Preference Capital

0

0

0

0

Reserves

4,099.26

3,949.09

3,280.74

2,604.92

Net Worth

4,207.05

4,056.82

3,388.21

2,712.24

Minority Interest

View Balance Sheet
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Revenue

4,707.04

4,768.72

2,797.33

2,026.84

yoy growth (%)

-1.29

70.47

38.01

7.13

Raw materials

-2,208.56

-2,175.13

-1,402.54

-1,056.4

As % of sales

46.92

45.61

50.13

52.12

Employee costs

-445.14

-401.88

-323.99

-238.14

View Profit & Loss
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Profit before tax

975.41

1,274.63

304.48

240.9

Depreciation

-235.48

-196.64

-183.85

-121.23

Tax paid

-225.32

-318.52

-37.43

-67.76

Working capital

145.83

684.91

246.73

42.81

Other operating items

View Cash Flow
Y/e 31 MarMar-2022Mar-2021Mar-2020Mar-2018

Growth matrix (%)

Revenue growth

-1.29

70.47

38.01

7.13

Op profit growth

-14.88

164.78

39.5

-1.22

EBIT growth

-20.08

241.8

23.97

-7.49

Net profit growth

-21.54

258.03

54.23

-13.41

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

5,040.83

6,040.55

4,935.57

4,813.51

2,831.72

Excise Duty

0

0

0

0

0

Net Sales

5,040.83

6,040.55

4,935.57

4,813.51

2,831.72

Other Operating Income

0

0

0

0

0

Other Income

26.34

6

15.3

23.66

5.92

Laurus Labs Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceutical Industries Ltd

SUNPHARMA

1,698.35

129.244,07,155.151,181.050.85,985.3398.33

Divis Laboratories Ltd

DIVISLAB

5,549.7

71.051,47,295.245940.542,297513.62

Cipla Ltd

CIPLA

1,444.25

25.071,16,664.331,438.150.94,134.87360.73

Torrent Pharmaceuticals Ltd

TORNTPHARM

3,183.9

59.031,07,673.274850.882,330222.38

Mankind Pharma Ltd

MANKIND

2,458.1

52.421,01,358.17416.3802,396.57334.17

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Laurus Labs Ltd

Management

Register Office

Registrar Office

Executive Director & CEO

CHAVA SATYANARAYANA

Executive Director & CFO

VENKATA RAVI KUMAR VANTARAM

Independent Director

Aruna Bhinge

Independent Director

Rajesh Koshy Chandy

Chairman & Independent Directo

Ravindranath Kancherla

Executive Director

Venkata Lakshmana Rao Chunduru

Independent Director

Karnam Sekar

Executive Director

KRISHNA CHAITANYA CHAVA

Vice President & CS

G Venkateswar Reddy

Executive Director

Soumya Chava

Independent Director

Ramesh Subrahmanian

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Laurus Labs is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company with a leadership position in generic active pharmaceutical ingredients (APIs) in selected high-growth therapeutic areas of anti-retrovirals (ARVs), Hepatitis C and Oncology. The company also manufactures APIs in oncology and other therapeutic areas, such as anti-asthma, ophthalmology, antidiabetics, cardiovascular, proton pump inhibitors (PPIs) amongst others. The company currently operates 4 manufacturing facilities in Visakhapatnam, Andhra Pradesh. Three of these facilities manufacture APIs and ingredients, while the fourth facility produces Finished Dosage Formulations (FDFs) and one API. The companys strategic and early investments in R&D and manufacturing infrastructure has enabled it to become one of the leading suppliers of APIs in the ARV therapeutic area to multi-national pharmaceutical formulation companies which cater to the large and fast-growing donor-funded access-to-medicines markets of Sub-Saharan Africa, South-East Asia and Latin America. The company also has growing synthesis and nutraceutical/ cosmeceutical ingredients businesses. Further, it is increasingly focused towards growing its integrated generics finished dosage forms (FDFs) business in which it has made significant investments.Laurus Labs operates in four business lines: Generics - APIs, Generics - FDFs, Synthesis and Ingredients. Its Generics - API business comprises the development, manufacture
Read More

Company FAQs

What is the Laurus Labs Ltd share price today?

The Laurus Labs Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹598.9 today.

What is the Market Cap of Laurus Labs Ltd?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Laurus Labs Ltd is ₹32295.83 Cr. as of 01 Apr ‘25

What is the PE and PB ratio of Laurus Labs Ltd?

The PE and PB ratios of Laurus Labs Ltd is 132.57 and 7.75 as of 01 Apr ‘25

What is the 52 Week High and Low of Laurus Labs Ltd?

The 52-week high/low is the highest and lowest price at which a Laurus Labs Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Laurus Labs Ltd is ₹385.45 and ₹646.2 as of 01 Apr ‘25

What is the CAGR of Laurus Labs Ltd?

Laurus Labs Ltd's CAGR for 5 Years at 57.18%, 3 Years at 1.26%, 1 Year at 56.34%, 6 Month at 32.31%, 3 Month at 4.43% and 1 Month at 16.35%.

What is the shareholding pattern of Laurus Labs Ltd?

The shareholding pattern of Laurus Labs Ltd is as follows:
Promoters - 27.62 %
Institutions - 38.30 %
Public - 34.08 %

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.